Effect of prostaglandin E1 and (the NO-donor) isosorbidedinitrate on thromboresistance in human in-vivo.
Sinzinger
H
H
Ludwig Boltzmann-Institute for Nuclear Medicine, Vienna, Austria.
Fitscha
P
P
Rauscha
F
F
O'Grady
J
J
Rogatti
W
W
Vane
J R
JR
D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006152:Cyclic GMP / Q000378:metabolism; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes; D007548:Isosorbide Dinitrate / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000378:metabolism; D009942:Organometallic Compounds; D015125:Oxyquinoline / Q000031:analogs & derivatives; D011877:Radionuclide Imaging; D011897:Random Allocation; D013927:Thrombosis / Q000517:prevention & control*
D007205:Indium Radioisotopes; D009942:Organometallic Compounds; C032950:indium oxine; D009569:Nitric Oxide; D015125:Oxyquinoline; D000527:Alprostadil; D006152:Cyclic GMP; D007548:Isosorbide Dinitrate